Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Solid Cancers 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms 1Colorectal Neoplasms 1

Interventions

Erlotinib Hydrochloride 21Bevacizumab 13Cisplatin 12Carboplatin 7Pemetrexed 6Gemcitabine 6Paclitaxel 5onartuzumab 4Docetaxel 3imgatuzumab 2sintilimab 1parsatuzumab 1lifastuzumab vedotin 1atezolizumab 1Vinorelbine 1RG-1507 monoclonal antibody 1Platinum Compounds 1Etoposide 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-Squamous Non-Small Cell Lung Cancer × parsatuzumab × Clear all
NCT01366131 2016-11-02

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Genentech, Inc.

Phase 2 Completed
104 enrolled
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡